证券日报网讯2月3日，海辰药业（300584）在互动平台回答投资者提问时表示，截至1月30日收盘，公 司股东户数为21149户。 ...

每经AI快讯，有投资者在投资者互动平台提问：请问贵公司什么时候公布2025年业绩预告？ 海辰药业（300584.SZ）1月30日在投资者互动平台表示，公司2025年度报告已预约至2026年4月25日对 外披露。 （文章来源：每日经济新闻） ...

Group 1 - The core point of the article highlights that Haisun Pharmaceutical experienced a 5% drop in stock price, trading at 50.30 yuan per share, with a total market capitalization of 6.036 billion yuan as of the report date [1] - Haisun Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, focuses on the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The company's revenue composition is primarily from cardiovascular drugs (87.12%), followed by antibiotics (5.69%), active pharmaceutical ingredients and intermediates (1.68%), digestive drugs (1.50%), antiviral drugs (1.47%), and other categories [1] Group 2 - Among the top circulating shareholders of Haisun Pharmaceutical, the Fuguo Fund's Fuguo Steady Growth Mixed A (010624) fund entered the top ten in the third quarter, holding 700,000 shares, which is 0.85% of the circulating shares [2] - The Fuguo Steady Growth Mixed A fund has a total scale of 6.13 billion yuan, with a year-to-date return of 5.37% and a one-year return of 36.61% [2] - The fund manager, Fan Yan, has been in the position for 10 years and 88 days, with the fund's best return during this period being 187.76% and the worst being -15.11% [3]

证券日报网讯1月14日，海辰药业（300584）在互动平台回答投资者提问时表示，截至2026年1月9日， 公司股东数为21073户。 ...

Group 1 - The core viewpoint of the article is that Haichen Pharmaceutical has achieved the required parameters for its lithium sulfide pilot line products and is preparing to send samples [2] - Sichuan Luocheng is a joint venture between the company's subsidiary Anqing Huichen and Saike Power, focusing on the development of solid-state battery binders [2] - The project is currently in the small-scale development stage [2]

Group 1 - The core viewpoint of the article is that Haichen Pharmaceutical has achieved the required parameters for its lithium sulfide pilot line products and is preparing to send samples [1] - Sichuan Luocheng is a joint venture between the company's subsidiary Anqing Huichen and Saike Power, focusing on the small-scale development of solid-state battery binders [1] - The project is currently still in the small-scale development phase [1]

Group 1 - Company Haitian Pharmaceutical (300584.SZ) announced on January 7 that the parameters of its lithium sulfide pilot line products have met the requirements and samples will soon be sent out [1] - Sichuan Luocheng is a joint venture between the company's subsidiary Anqing Huicheng and Saike Power, which has been closely collaborating on the small-scale development of solid-state battery binders, currently still in the small-scale development phase [1] Group 2 - Investors inquired about the recent acceleration of the industrialization of sulfide solid-state batteries, specifically regarding the current pilot production capacity utilization rate, product purity, and whether samples have been sent to battery companies for verification [2] - Questions were raised about the completion of the small-scale process for the solid-solid contact binder, its bonding strength, and interface impedance, as well as whether Saike Power's experience in battery system integration supports the mass production of the binder [2]

证券代码：300584 证券简称：海辰药业 公告编号：2026-001 南京海辰药业股份有限公司 关于控股股东、实际控制人股份全部解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、股东股份累计被质押的情况 截至公告披露日，曹于平先生及其妻子姜晓群女士所持质押股份情况如下： | | | | 本次解除 | 本次解除 | | | 已质押股份 情况 | | 未质押股份 情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | 持股 | 质押前质 | 质押后质 | 占其所持 | 占公司总 | | | | | | 名称 | 持股数量 | 比例 | 押股份数 | 押股份数 | 股份比例 | 股本比例 | 已质押股份 限售和冻结 | 占已质押 | 未质押股份 限售和冻结 | 占未质押 | | | | | 量 | 量 | | | 数量 | 股份比例 | 数量 | 股份比例 | | 曹于平 | 50,491,306 | 42.08% | 4,000,00 ...

Group 1 - The company has initiated trial production for its VC project, indicating progress in its development phase [1] - The company acknowledges that it still needs to undergo a capacity ramp-up process, which is a critical step before full-scale production can be achieved [1]

Core Insights - The chemical pharmaceutical sector experienced a rise of 1.22% on December 17, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3870.28, up 1.19%, while the Shenzhen Component Index closed at 13224.51, up 2.4% [1] Group 1: Stock Performance - Hai Chen Pharmaceutical (300584) closed at 50.55, with a gain of 6.04% and a trading volume of 68,600 shares, amounting to a transaction value of 342 million yuan [1] - Other notable performers included Yahui Pharmaceutical (688176) with a closing price of 10.35, up 5.50%, and ST Renfu (600079) at 18.10, up 4.99% [1] - The overall trading volume and transaction values for various stocks in the sector indicate strong market activity, with ST Renfu recording a trading volume of 1.25 million shares and a transaction value of 2.173 billion yuan [1] Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 554 million yuan from institutional investors, while retail investors contributed a net inflow of 799 million yuan [2][3] - The main stocks experiencing significant fund flow included ST Renfu, which had a net inflow of 112 million yuan from institutional investors, while Hai Chen Pharmaceutical saw a net outflow of 18.84 million yuan from retail investors [3] - The overall fund flow dynamics suggest a divergence in investment behavior between institutional and retail investors within the sector [2][3]